NexGard label claims expansion approved

Boehringer Ingelheim Animal Health has received approval from the European Commission and Australian Pesticides and Veterinary Medicines Authority to expand the label claims for its NexGard (afoxolaner) brands for the treatment of cutaneous disease demodicosis and sarcoptic mange, the former being one of the most severe skin diseases in dogs and potentially life-threatening, and the latter a form of generalized dermatitis in dogs that is often difficult to diagnose. The approvals are based on three trial studies and two field studies. The canine demodicosis trials showed efficiency of afoxolaner at more than 98%, with the studies on sarcoptic mange showing almost 100% efficacy against mites after just one use.
Professor Fred Beugnet, head of global veterinary technical services for parasiticides at Boehringer Ingelheim, said: “Sarcoptes mites are not only easily transferred between dogs but are zoonotic parasites which can be passed from animals to humans. This is why the treatment of this disease is crucial for animals’ as well as humans’ health. Both field studies in Europe clearly confirmed the safety and efficacy against the two diseases of the administration of both NexGard and NexGard Spectra. “